. Author manuscript; available in PMC: 2018 Jul 5.

Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2017 May 22;17(6):347–353. doi: 10.1016/j.clml.2017.05.008

Table 4.

Pharmacokinetic Parameter Estimates of Lenalidomide After Oral Administration of 25 mg (n = 14)

Pharmacokinetic Parameter	gMean	SD
HL_Lambda_z, h	3.93	1.38
Tmax, h	1.42	0.78
Cmax, μmol/L	1.51	0.60
AUCINF_pred, h/μmol/L	7.80	3.90
V/F, L	70.13	34.4
CL/F, L/h	12.35	5.7

Abbreviations: AUCINF_pred = area under the curve from dosing time extrapolated to infinity, based on last predicted concentration; CL/F = Clearance/Fraction absorbed; Cmax = maximum plasma concentration; gMean = geometric mean; HL_Lambda_z = terminal half-life (ln(2)/terminal slope); Tmax = time of maximum observed concentration; V/F = Clearance/Fraction absorbed.